93129-68-1Relevant articles and documents
NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY
-
Page/Page column 50, (2021/11/20)
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting
Novel potent antagonists of transient receptor potential channel, vanilloid subfamily member 1: Structure-activity relationship of 1,3-diarylalkyl thioureas possessing new vanilloid equivalents
Suh, Young-Ger,Lee, Yong-Sil,Min, Kyung-Hoon,Park, Ok-Hui,Kim, Jin-Kwan,Seung, Ho-Sun,Seo, Seung-Yong,Lee, Bo-Young,Nam, Yeon-Hee,Lee, Kwang-Ok,Kim, Hee-Doo,Park, Hyeung-Geun,Lee, Jeewoo,Oh, Uhtaek,Lim, Ju-Ok,Kang, Sang-Uk,Kil, Min-Jung,Koo, Jae-Yeon,Shin, Song Seok,Joo, Yung-Hyup,Kim, Jin Kwan,Jeong, Yeon-Su,Kim, Sun-Young,Park, Young-Ho
, p. 5823 - 5836 (2007/10/03)
Recently, 1,3-diarylalkyl thioureas have merged as one of the promising nonvanilloid TRPV1 antagonists possessing excellent therapeutic potential in pain regulation. In this paper, the full structure-activity relationship for TRPV1 antagonism of a novel series of 1,3-diarylalky thioureas is reported. Exploration of the structure-activity relationship, by systemically modulating three essential pharmacophoric regions, led to six examples of 1,3-dibenzyl thioureas, which exhibit Ca2+ uptake inhibition in rat DRG neuron with IC50 between 10 and 100 nM.
PHENYLALKYL AND PYRIDYLALKYL PIPERAZINE DERIVATIVES
-
Page 142, (2010/02/07)
This invention relates to compounds of the formula (1) wherein R1, R3, R4, X1, and X2 are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system and other disorders.